Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803-827

Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803-827

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Revista Portuguesa de Pneumologia (English Edition) - Volume 15, Issue 3, May–June 2009, Pages 555-559

Wojciech MD MSc,